National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 3830-3831 [2022-01364]
Download as PDF
<![CDATA[
3830
Federal Register / Vol. 87, No. 16 / Tuesday, January 25, 2022 / Notices
Health, 6701 Rockledge Drive, Bethesda, MD
20782, 301–402–4788, sarita.sastry@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
January 19, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–01358 Filed 1–24–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency
Coordinating Committee Meeting
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Diabetes Mellitus
Interagency Coordinating Committee
(DMICC) will hold a meeting on March
8, 2022. The topic for this meeting will
be ‘‘Opportunities for Research
Supported by the Special Statutory
Funding Program for Type 1 Diabetes
Research.’’ The meeting is open to the
public.
DATES: The meeting will be held on
March 8, 2022 from 8:30 a.m. to 4:45
p.m. EDT.
ADDRESSES: The meeting will be held
via an online video conferencing
platform. Virtual attendance for the
meeting will be accessible to members
of the public who register at https://
www.scgcorp.com/dmicc2022/
Registration at least 5 days prior to the
workshop.
FOR FURTHER INFORMATION CONTACT: For
further information concerning this
meeting, including a draft agenda,
which will be posted when available,
see the DMICC website,
www.diabetescommittee.gov, or contact
Dr. William Cefalu, Director, Division of
Diabetes, Endocrinology, and Metabolic
Diseases, National Institute of Diabetes
and Digestive and Kidney Diseases,
6707 Democracy Boulevard, Democracy
2, Room 6037, Bethesda, MD 20892,
telephone: 301–435–1011; email:
dmicc@mail.nih.gov.
SUPPLEMENTARY INFORMATION: In
accordance with 42 U.S.C. 285c–3, the
DMICC, chaired by the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) and
comprising members of the Department
of Health and Human Services and other
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:19 Jan 24, 2022
Jkt 256001
federal agencies that support diabetesrelated activities, facilitates cooperation,
communication, and collaboration on
diabetes among government entities.
DMICC meetings, held several times a
year, provide an opportunity for
Committee members to learn about and
discuss current and future diabetes
programs in DMICC member
organizations and to identify
opportunities for collaboration. The
March 8, 2022 DMICC meeting will
focus on ‘‘Opportunities for Research
Supported by the Special Statutory
Funding Program for Type 1 Diabetes
Research.’’ Any interested person may
file written comments with the
Committee by forwarding their
statement to the contact person listed on
this notice. The statement should
include the name, address, telephone
number and, when applicable, the
business or professional affiliation of
the interested person. Because of time
constraints for the meeting, there will
not be time on the agenda for oral
comments from members of the public.
Members of the public who would
like to receive email notification about
future DMICC meetings should register
for the listserv available on the DMICC
website, www.diabetescommittee.gov.
Dated: January 19, 2022.
Bruce Tibor Roberts,
Executive Secretary, DMICC, Office of
Scientific Program and Policy Analysis,
National Institute of Diabetes and Digestive
and Kidney Diseases, National Institutes of
Health.
[FR Doc. 2022–01345 Filed 1–24–22; 8:45 am]
BILLING CODE 4140–01–P
Name of Committee: National Cancer
Institute Clinical Trials and Translational
Research Advisory Committee.
Date: March 16, 2022.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: Strategic Discussion of NCI’s
Clinical and Translational Research
Programs.
Place: National Cancer Institute, 9609
Medical Center Drive, Rockville, MD 20850
(Virtual Meeting).
Contact Person: Sheila A. Prindiville, M.D.,
M.P.H., Director, Coordinating Center for
Clinical Trials, National Cancer Institute,
National Institutes of Health, 9609 Medical
Center Drive, Room 6W136, Rockville, MD
20850, 240–276–6173, prindivs@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/ctac/ctac.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: January 19, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–01329 Filed 1–24–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer Institute
Clinical Trials and Translational
Research Advisory Committee.
The meeting will be held as a virtual
meeting and is open to the public.
Individuals who plan to view the virtual
meeting and need special assistance or
other reasonable accommodations to
view the meeting, should notify the
Contact Person listed below in advance
of the meeting. The meeting will be
videocast and can be accessed from the
NIH Videocasting and Podcasting
website (https://videocast.nih.gov).
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
E:\FR\FM\25JAN1.SGM
25JAN1
Federal Register / Vol. 87, No. 16 / Tuesday, January 25, 2022 / Notices
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Emergency Awards:
Antiviral Drug Discovery (AViDD) Centers for
Pathogens of Pandemic Concern (U19
Clinical Trials Not Allowed).
Date: February 9–17, 2022.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E70A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Soheyla Saadi, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3E70A, Rockville, MD
20852, 301–435–0903, saadisoh@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 19, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–01364 Filed 1–24–22; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKJM1Z7X2PROD with NOTICES
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development,
Initial Review Group; Health, Behavior, and
Context Study Section.
Date: February 28, 2022.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
17:19 Jan 24, 2022
Jkt 256001
Dated: January 20, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–01424 Filed 1–24–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
BILLING CODE 4140–01–P
VerDate Sep<11>2014
Place: Eunice Kennedy Shriver National
Institute of Child Health and Human
Development, National Institutes of Health,
6710B Rockledge Drive, Room 2137C,
Bethesda, MD 20892 (Video Assisted
Meeting).
Contact Person: Kimberly L. Houston, MD,
Scientific Review Officer, Scientific Review
Branch, Eunice Kennedy Shriver National
Institute of Child Health and Human
Development, National Institutes of Health,
6710B Rockledge Drive, Room 2137C,
Bethesda, MD 20892, (301) 827–4902,
kimberly.houston@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Child Psychopathology and
Developmental Disabilities Study Section.
Date: February 22–23, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Karen Elizabeth Seymour,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 1000–E,
Bethesda, MD 20892, (301) 443–9485,
karen.seymour@nih.gov.
Name of Committee: Endocrinology,
Metabolism, Nutrition and Reproductive
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
3831
Sciences Integrated Review Group;
Pathophysiology of Obesity and Metabolic
Disease Study Section.
Date: February 24–25, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Raul Rojas, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6185,
Bethesda, MD 20892, (301) 451–6319, rojasr@
mail.nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Cancer, Heart, and Sleep Epidemiology A
Study Section.
Date: February 24–25, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Denise Wiesch, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3138,
MSC 7770, Bethesda, MD 20892, (301) 437–
3478, wieschd@csr.nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Health Services: Quality and Effectiveness
Study Section.
Date: February 24–25, 2022.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Angela Denise Thrasher,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1000J,
Bethesda, MD 20892, (301) 480–6894,
thrasherad@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR20–117:
Maximizing Investigators’ Research Award
(MIRA) for Early Stage Investigators (R35—
Clinical Trial Optional).
Date: February 28–March 1, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Rebecca Catherine
Burgess, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 480–8034,
rebecca.burgess@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA RM
21–025: Faculty Institutional Recruitment for
Sustainable Transformation (FIRST) Program.
Date: February 28–March 1, 2022.
Time: 9:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\25JAN1.SGM
25JAN1
]]>Agencies
[Federal Register Volume 87, Number 16 (Tuesday, January 25, 2022)]
[Notices]
[Pages 3830-3831]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01364]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which
[[Page 3831]]
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Emergency Awards: Antiviral Drug
Discovery (AViDD) Centers for Pathogens of Pandemic Concern (U19
Clinical Trials Not Allowed).
Date: February 9-17, 2022.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3E70A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Soheyla Saadi, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room 3E70A, Rockville, MD
20852, 301-435-0903, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: January 19, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-01364 Filed 1-24-22; 8:45 am]
BILLING CODE 4140-01-P
